ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Astellas to acquire eye-focused gene therapy firm Quethera

by Michael McCoy
August 17, 2018 | APPEARED IN VOLUME 96, ISSUE 33

 

Astellas Pharma will spend up to $108 million to acquire Quethera, a British gene therapy developer founded in 2015 based on the research of a University of Cambridge professor. Quethera is using recombinant adeno-associated viral vectors to introduce therapeutic genes into retinal cells for the treatment of glaucoma. Its lead candidate has yet to enter clinical trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment